Loading stock data…
$3.10-0.53 (-14.60%)
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.10 with a market capitalization of $136M. Wall Street consensus targets $17.50 (2 analysts), implying a +464.5% move over the next 12 months. The stock is currently near its 52-week low of $3.01, remaining 57.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | -$8.79M↓ | -$8.41M↓ | -$7.78M↓ | -$6.84M |
| Net Income | — | -$115.35M↑ | -$124.30M↓ | -$26.68M↓ | -$16.30M |
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacte...